Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
American Journal of Physiology. Cell Physiology|June 13, 2003
Functional role of the NPxxY motif in internalization of the type 2 vasopressin receptor in LLC-PK1 cellsRichard Bouley, Tian-Xiao Sun, Melissa Chenard, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)David J Witter, Paul Harrington, Kevin J Wilson, et al.
Neoplasia (New York, N.Y.)|December 25, 2008
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse modelsBrian B Haines, Kimberly A Bettano, Melissa Chenard, et al.
Biochemistry|January 24, 2014
Divergent kinetics differentiate the mechanism of action of two HDAC inhibitorsAstrid M Kral, Nicole Ozerova, Joshua Close, et al.
Molecular Cancer Therapeutics|March 18, 2016
An Unbiased Oncology Compound Screen to Identify Novel Combination StrategiesJennifer O'Neil, Yair Benita, Igor Feldman, et al.
Bioorganic & Medicinal Chemistry Letters|February 29, 2008
Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1)Kevin J Wilson, David J Witter, Jonathan B Grimm, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2009
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2)Richard W Heidebrecht, Melissa Chenard, Joshua Close, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2)Joey L Methot, Christopher L Hamblett, Dawn M Mampreian, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2009
Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimizationSolomon D Kattar, Laura M Surdi, Anna Zabierek, et al.
Pageof 2